Featured Research

from universities, journals, and other organizations

Combination treatment regimen not effective against advanced melanoma

Date:
June 6, 2010
Source:
University of Pittsburgh Schools of the Health Sciences
Summary:
The combination of two different chemotherapies and a molecular inhibitor previously approved to treat kidney and liver cancers is not effective against advanced melanoma, according to new results.

The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation June 6 at the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

"With each new study, we learn something important about the treatment of melanoma," said John M. Kirkwood, M.D., professor of medicine, University of Pittsburgh School of Medicine, and leader of the University of Pittsburgh Cancer Institute's (UPCI) melanoma and skin cancer program. "With this study, we learned that the addition of sorafenib, a molecular inhibitor, to a traditional chemotherapy regimen does not improve patient survival."

The phase III trial, which was sponsored by the Eastern Cooperative Oncology Group (ECOG), enrolled 823 patients from seven different sites across the country over 34 months. The primary goal of the study was to determine whether the addition of sorafenib, a molecular targeting agent, would improve survival rates for patients with metastatic melanoma when added to the chemotherapy combination of carboplatin and paclitaxel. Patients either received the chemotherapy combination alone or with sorafenib.

"While this study didn't confirm the very promising results of phase II studies with sorafenib, it is important to share its findings since the double chemotherapy combination of carboplatin and paclitaxel has achieved results that eclipse previous chemotherapy results in large phase III trials. These results take us one step closer to understanding how to most effectively treat metastatic melanoma," said Dr. Kirkwood.

Melanoma is a rare form of skin cancer, but it causes the majority of skin-cancer related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide. Surgery effectively cures early disease, but once it has spread to regional lymph nodes or distant sites, a cure is more elusive. Only two therapies in current usage have been approved by the U.S. Food and Drug Administration for treatment of advanced melanoma, and neither has been shown to prolong survival.


Story Source:

The above story is based on materials provided by University of Pittsburgh Schools of the Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Schools of the Health Sciences. "Combination treatment regimen not effective against advanced melanoma." ScienceDaily. ScienceDaily, 6 June 2010. <www.sciencedaily.com/releases/2010/06/100606104825.htm>.
University of Pittsburgh Schools of the Health Sciences. (2010, June 6). Combination treatment regimen not effective against advanced melanoma. ScienceDaily. Retrieved August 21, 2014 from www.sciencedaily.com/releases/2010/06/100606104825.htm
University of Pittsburgh Schools of the Health Sciences. "Combination treatment regimen not effective against advanced melanoma." ScienceDaily. www.sciencedaily.com/releases/2010/06/100606104825.htm (accessed August 21, 2014).

Share This




More Health & Medicine News

Thursday, August 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins